Clinical-stage biopharmaceutical company Eloxx Pharmaceuticals Inc (Nasdaq:ELOX) announced on Wednesday the publication of results from its Phase 2a proof-of-mechanism study of exaluren in nonsense mutation Alport syndrome in the Journal of Clinical Investigation (JCI).
In the open-label Phase 2a study, three patients aged 12 to 18 years with autosomal recessive Alport syndrome and a COL4A4 premature termination codon received daily subcutaneous exaluren (0.75 mg/kg) for eight weeks. The primary endpoint was safety and tolerability, while secondary endpoints included pre- and post-treatment kidney biopsy assessments.
Kidney biopsies showed increased collagen IV abundance and partially improved podocyte morphology in all three participants.
Masked machine-learning analysis of electron microscopy images showed foot process width reductions of 46%, 14% and 16%. Exploratory analysis showed increased filtration slit density in all participants; mean density increased by 50%, reaching more than 80% of healthy control values.
Eloxx noted that changes in proteinuria were inconsistent, and interpretation was limited by intra-patient variability and the short treatment duration. Hematuria persisted in all participants.
Exaluren was well tolerated, with no serious adverse events, nephrotoxicity or ototoxicity.
The findings support the ongoing Phase 2b EXACT study.
Exaluren (formerly ELX-02) is an investigational, ribosome-targeting glycoside designed to accumulate in kidney cells and promote readthrough of premature stop codons, but not native stop codons, to enable production of full-length, functional proteins.
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment
Aelis Farma announces receipt of second positive safety recommendation for Down syndrome trial